drugset / Trial / NCT00445432

A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease

NCT00445432

Phase 2/3 Completed 82 enrolled Abbott Eisai Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To demonstrate the efficacy and safety of adalimumab for the maintenance of clinical remission in Japanese subjects with Crohn's disease.

Timeline

Start
2007-03
Primary completion
2009-03
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous
Subject Adalimumab Monoclonal antibody 80 mg Subcutaneous

Indications